The US Food and Drug Administration (FDA) has approved Belsomra (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep.
A husband-and-wife team are pushing the FDA to get readable quantitative data about drugs to doctors and patients, reports NPR. As an example, the team developed a drug facts box for Lunesta.
Men with sleep apnea are more likely to suffer from low testosterone, but testosterone products can actually worsen sleep apnea, reports DrugWatch.com.
Consumer Reports Best Buy Drugs compares the effectiveness, safety, and price of the most common insomnia medications.
As of this week, three new options are available for generic Sunovion Pharmaceuticals Inc's Lunesta (eszopiclone), a pharmacological treatment for insomnia.
Hyderabad, India-based Dr. Reddy’s Laboratories has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg, and 3 mg, a therapeutic equivalent generic version of Lunesta (eszopiclone) tablets C-IV in the US market.
Psychiatrists ascribe the highest level of unmet need in insomnia treatment to be for new therapies with a reduced risk of abuse and tolerance, according to a recent Decision Resources Group's report on insomnia.
Sleeping pills and anti-anxiety drugs and have been linked to an increased risk of death, according to new research from the University of Warwick.
The large study, published in BMJ, shows that several anxiolytic (anti-anxiety) drugs or hypnotic drugs (sleeping pills) are associated with a doubling in the risk of mortality.
Vanda Pharmaceuticals Inc this week announced the availability of Hetlioz. Hetlioz is the first treatment approved by the US Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a chronic circadian rhythm disorder that affects up to 70% of people who are totally blind.
The FDA today approved Hetlioz (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). Hetlioz, manufactured by Vanda Pharmaceuticals, treats the chronic circadian rhythm disorder that affects up to 70% of totally blind individuals.
Jazz Pharmaceuticals has acquired rights to ADX-N05, a compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy, from Aerial BioPharma, LLC, for $125 million.
Two marketers of genetically customized nutritional supplements have agreed to settle Federal Trade Commission charges of deceptive advertising for claims that their personalized nutritional supplements treat insomnia.
Galleon is building a drug discovery and development platform that focuses on the pharmaceutical treatment of sleep apnea and related breathing-control disorders. It was recently recognized for its scientific abstracts.
London law firm Hodge Jones & Allen has filed a class action lawsuit on behalf of 38 narcolepsy sufferers against GlaxoSmithKline for GSK's Pandemrix swine flu vaccine. The claimants were diagnosed with narcolepsy after receiving the vaccine.
A new study has concluded that taking the drug modafinil, typically used to treat sleep disorders, in combination with antidepressants reduces the severity of depression more effectively than taking antidepressants alone.
The US Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda Pharmaceutical's application for tasimelteon for the treatment of Non-24-Hour Disorder.
Most patients take Ambien to sleep, but in some specific cases it seems the insomnia pill can assist brain-injured patients to wake out of minimally conscious states.
Lupin Pharmaceuticals Inc has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg strengths from the FDA.
The agency determined that the safety data do not support the approval of Suvorexant in 30 mg and 40 mg doses.
Tasimelteon, used to treat Non-24 Hour Sleep-Wake Disorder, allows the body to re-synchronize, increasing night-time sleep and reducing day-time sleep.